Adipo presented their findings at the American Diabetes Association 84th Scientific Sessions. Image courtesy of Adipo.

News Release

INDIANAPOLIS — Adipo Therapeutics, LLC, a late pre-clinical biopharmaceutical company developing treatments for obesity and related metabolic disorders, announced a key study demonstrating promising results using human tissue samples.

Unlike popular obesity GLP-1 injections such as Ozempic, which cause weight loss through calorie deficit, Adipo aims to address weight loss by “converting energy-storing white fat into metabolically beneficial, energy-burning brown fat using cutting-edge technology in the form of Notch-inhibiting nanoparticles.”

According to Adipo, animal studies have demonstrated “weight loss and improved blood glucose and lipid control with no change in calorie intake.”

In Adipo’s new study, human tissue, obtained from obese patients undergoing bariatric surgery, was used to test the conversion of white adipose fat to brown fat. Results showed “ADPO-002, a Notch inhibitor, promotes the expression of two key browning biomarkers.”

Review the slides from a presentation Adipo gave at the American Diabetes Association 84th Scientific Sessions here.